As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026

11th March 2026 Uncategorised 0

Eli Lilly continued staggering sales growth in the fourth quarter, nearly tripling that of any other top 25 drugmaker. Meanwhile, most companies are expecting a slowdown in growth in 2026.

More: As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026
Source: fierce